

Triple Analysis: Breast Cancer, Colorectal Cancer and Peptides

Published: 2011-NOV-14

Pages: 2875

Format: PDF

Price: 4495 USD (Single User License)

Description

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer

The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer.

This part is based on the following publication:

Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

Part II: Colorectal Cancer

The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part III: Peptides

The cancer peptide drug report part comprises defined and up to date development strategies for 152 peptide drugs in oncology within the portfolio of 104 companies world-wide, from Ceased to Marketed. The report extensively analyses their 123 identified drug targets, organized into 103 drug target strategies, and assesses them in 56 cancer indications.

This part is based on the following publication:

Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

- * Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- * Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- * Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- * Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- * Supporting development of integrative molecule, pathway and disease area strategies

BioMarket Group - A Global Online Aggregator of Life Science Market Research

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Table of Contents

Key Topics Covered:

Part I: Breast Cancer

5.1	The Scope of this Report	29
6	Consider the Therapeutic Breast Cancer Target for the Highest Therapeutic Outcome and Return on Investment (207 Drug Targets)	33-376
7	The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Breast Cancer Therapeutic Pipeline? (193 Drug Target Strategies and 405 Drugs)	377-441
8	Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Different Compound Strategies)	442-488
9	Pipeline and Portfolio Planning: Competitive Benchmarking of Breast Cancer Therapeutic Pipeline by Investigator (220 Investigators)	489-891
11	Drug Index	893
12	Company Index	905

Figures: Includes 7 Figures
Tables: Includes 274 Tables
Total Number of Pages: 913

Part II: Colorectal Cancer

5.1	The Scope of this Report	28
6	Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets)	32-451
7	Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs)	452-699
8	Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies)	700-745
9	Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies)	746-1,039
10	Disclaimer	1040
11	Drug Index	1041
12	Company Index	1050

Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part III: Peptides

5.1	The Scope of this Report	26
6	Consider the Therapeutic Target Among Peptide Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (123 Drug Targets)	30-248
7	Emerging New Products to Established Ones: Drug Target Strategies of Peptide Drugs in Oncology by their Highest Stage of Development (103 Drug Targets Strategies and 152 Peptide Drugs)	249-372
8	Selecting Indication for Peptide Drugs in Oncology (56 Cancer Indications)	373-441
9	Pipeline and Portfolio Planning: Competitive Benchmarking of the Peptide Drug Pipeline in Oncology by Investigator (104 Investigators and 152 Peptide Drugs)	442-895
10	Disclaimer	896
11	Drug Index	897
12	Company Index	902

Figures: Includes 5 Figures
Tables: Includes 207 Tables
Total Number of Pages: 906

Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/triple-analysis-breast-cancer-colorectal-cancer-and-peptides.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioMarket Group
Björnåsvägen 21
11419 STOCKHOLM

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit <http://www.biomarketgroup.com/market-research-report/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Triple Analysis: Breast Cancer, Colorectal Cancer and Peptides**

Web Address: <http://www.biomarketgroup.com/market-research-report/triple-analysis-breast-cancer-colorectal-cancer-and-peptides.html>

Format: PDF

Price: 4495 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number:

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
 - Master Card
 - Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

- Pay by check:**

Please post the check, accompanied by this form, to:
BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/market-research-report/biomarket-group-full-terms-and-conditions/>

Please fax this form to: +46-8-56849191